enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shares traded up 2.2% during mid-day trading on Thursday . The company traded as high as $1.15 and last traded at $0.93. 300 shares changed hands during trading, a decline of 97% from the average session volume of 8,611 shares. The stock had previously closed at $0.91.
enGene Stock Performance
The business’s 50 day moving average price is $0.80 and its 200-day moving average price is $0.80.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Recommended Stories
- Five stocks we like better than enGene
- The Significance of Brokerage Rankings in Stock Selection
- BigBear.ai: Why a 90% Rally Could Be Just the Start
- What Are Growth Stocks and Investing in Them
- 5 Hot Stocks With Summer Buybacks You Can Cash In On
- How to Calculate Inflation Rate
- Why Now Could Be the Smartest Time to Buy Crypto Stocks
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
